4//SEC Filing
WEAVER GREGORY L 4
Accession 0001437749-21-016573
CIK 0001488039other
Filed
Jul 6, 8:00 PM ET
Accepted
Jul 7, 4:29 PM ET
Size
20.5 KB
Accession
0001437749-21-016573
Insider Transaction Report
Form 4
WEAVER GREGORY L
Director
Transactions
- Exercise/Conversion
Common Stock
2021-07-02$5.64/sh+4,581$25,837→ 4,581 total - Exercise/Conversion
Common Stock
2021-07-02$2.38/sh+45,000$107,100→ 49,581 total - Exercise/Conversion
Common Stock
2021-07-02$2.52/sh+45,000$113,400→ 94,581 total - Exercise/Conversion
Common Stock
2021-07-02$1.70/sh+70,000$119,000→ 164,581 total - Tax Payment
Common Stock
2021-07-02$6.40/sh−57,084$365,338→ 107,497 total - Sale
Common Stock
2021-07-02$5.58/sh−107,497$599,833→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2021-07-02−4,581→ 0 totalExercise: $5.64→ Common Stock (4,581 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-07-02−45,000→ 0 totalExercise: $2.38→ Common Stock (45,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-07-02−45,000→ 0 totalExercise: $2.52→ Common Stock (45,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-07-02−70,000→ 0 totalExercise: $1.70→ Common Stock (70,000 underlying)
Footnotes (6)
- [F1]Reflects the Nasdaq closing price of the Issuer's common stock on July 01, 2021.
- [F2]Reflects the weighted average sale price. The range of prices for such transaction is $5.51 to $5.65. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
- [F4]These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
- [F5]These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
- [F6]These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date.
Documents
Issuer
ATOSSA THERAPEUTICS, INC.
CIK 0001488039
Entity typeother
Related Parties
1- filerCIK 0001251779
Filing Metadata
- Form type
- 4
- Filed
- Jul 6, 8:00 PM ET
- Accepted
- Jul 7, 4:29 PM ET
- Size
- 20.5 KB